CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives EUA from DCGI for ZyCoV-D20-08-2021
20-08-2021
Cadila inks pact with Italian firm to launch generic product in US
Under the agreement, CHEMI will manufacture and supply the Enoxaparin Sodium Injection which Zydus will commercialise in the US20-08-2021
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus partners with CHEMI of Italy to launch Enoxaparin Sodium Injection in the United States20-08-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the conference call held on August 11 2021 post Q1 results20-08-2021
Buy Cadila Healthcare; target of Rs 670: Motilal Oswal
Motilal Oswal is bullish on Cadila Healthcare recommended buy rating on the stock with a target price of Rs 670 in its research report dated August 11, 2021.19-08-2021
CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates18-08-2021
Zydus Cadila gets tentative nod from USFDA for cancer drug
Drug garnered 320 approvals; 400 ANDAs pending17-08-2021
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives tentative approval from USFDA for Lenalidomide Capsules17-08-2021
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of Loss of share certificate17-08-2021
CADILA HEALTHCARE LTD. - 532321 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Transcript of 26th AGM14-08-2021